Insmed (NASDAQ:INSM) Posts Earnings Results

Insmed (NASDAQ:INSM) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61, FiscalAI reports. The company had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative return on equity of 122.43% and a negative net margin of 76.94%.The firm’s revenue was up 296.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.70) EPS.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI launch momentum accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, with approximately 7,000 new patient starts and more than 6,300 cumulative prescribers. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.4 billion from above $1 billion.
• Insmed increased its estimated global peak sales opportunity for BRINSUPRI to more than $7 billion, citing expanding diagnosis, strong persistence and payer access, and the potential for broader use among patients with comorbid COPD or asthma. The company said prescribing depth and refill behavior are tracking at or ahead of internal expectations.
• TPIP data strengthened the company’s confidence in its pipeline centerpiece. In a 12-month PAH open-label extension, patients maintained or improved efficacy measures, 65% reached refined low-risk status, treatment continuation was 91%, and no new safety signals emerged; Phase III programs in PAH and PH-ILD are enrolling, with PPF and IPF studies planned.
• ARIKAYCE revenue rose 8% year over year to $116.3 million, while Insmed reiterated 2026 guidance of $450 million–$470 million. The company has submitted for a U.S. label expansion into newly diagnosed MAC lung disease and expects a Japanese submission in the second half of 2026, potentially supporting launches in 2027.
• Insmed reported approximately $1.2 billion in cash and reiterated expectations for cash-flow positivity in 2027 without additional capital raises, despite planned investment in TPIP Phase III trials, BRINSUPRI advertising, and Japanese commercial infrastructure. Management also noted that European commercialization is less attractive because of budget constraints and limited willingness to pay for innovation.

Insmed Stock Performance

INSM stock traded down $1.45 on Friday, reaching $131.10. 4,904,073 shares of the company were exchanged, compared to its average volume of 3,072,772. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The stock’s fifty day moving average price is $105.14 and its 200 day moving average price is $129.23. The firm has a market capitalization of $28.42 billion, a PE ratio of -31.90 and a beta of 0.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Raymond James Financial assumed coverage on Insmed in a research report on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Royal Bank Of Canada decreased their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Jefferies Financial Group reissued a “buy” rating and set a $175.00 target price on shares of Insmed in a research report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $235.00 price target on shares of Insmed in a report on Tuesday, July 28th. Finally, Mizuho set a $192.00 price target on Insmed in a research report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $205.26.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Insider Activity at Insmed

In other Insmed news, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer directly owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This represents a 2.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the transaction, the insider owned 37,648 shares in the company, valued at approximately $3,607,431.36. The trade was a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 54,590 shares of company stock valued at $5,793,738 in the last quarter. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Darwin Global Management Ltd. raised its holdings in Insmed by 2.3% in the 4th quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after acquiring an additional 475,832 shares in the last quarter. State Street Corp grew its holdings in shares of Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares in the last quarter. RTW Investments LP increased its position in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after purchasing an additional 1,758,321 shares during the period. Orbis Allan Gray Ltd increased its position in shares of Insmed by 28.6% during the fourth quarter. Orbis Allan Gray Ltd now owns 4,179,957 shares of the biopharmaceutical company’s stock valued at $727,480,000 after purchasing an additional 929,089 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Insmed by 36.1% in the fourth quarter. Invesco Ltd. now owns 2,726,857 shares of the biopharmaceutical company’s stock valued at $474,582,000 after purchasing an additional 722,986 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.